Security
NSPR.WS · InspireMD, Inc.
NSPR.WSAMEXWarrantHistorical · closed Jun 7, 2021CIK 1433607Updated Sep 24, 2026
Name history
Saguaro Resources, Inc. · through Apr 1, 2011
Current security for this SEC filerNSPR · NASDAQ
NSPR.WS price & chart
Historical security
This listing closed Jun 7, 2021. Live provider charts are shown only for current listings.
Current security: NSPR
About the company
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
4 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 69,404,000Source | 46,807,000Source | 47,643,000Source | 24,653,000Source |
| Property, Plant and Equipment, NetUSD | 3,584,000Source | 2,371,000Source | 1,060,000Source | 917,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,939,000Source | 18,916,000Source | 9,640,000Source | 4,632,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,168,000Source | 1,572,000Source | 1,804,000Source | 1,034,000Source |
| Inventory, NetUSD | 3,396,000Source | 2,570,000Source | 2,106,000Source | 1,621,000Source |
| Assets, CurrentUSD | 61,471,000Source | 40,521,000Source | 44,159,000Source | 21,326,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,758,000Source | 2,360,000Source | 1,473,000Source | 1,554,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,203,000Source | 10,721,000Source | 8,142,000Source | 7,260,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 357,489,000Source | 289,589,000Source | 261,000,000Source | 218,977,000Source |
| Retained Earnings (Accumulated Deficit)USD | -302,292,000Source | -253,506,000Source | -221,501,000Source | -201,585,000Source |
| Stockholders' Equity Attributable to ParentUSD | 55,201,000Source | 36,086,000Source | 39,501,000Source | 17,393,000Source |
| Liabilities and EquityUSD | 69,404,000Source | 46,807,000Source | 47,643,000Source | 24,653,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,712,000Source | 7,678,000Source | 6,020,000Source | 5,070,000Source |
| Operating Lease, Liability, CurrentUSD | 1,066,000Source | 542,000Source | 557,000Source | 419,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,224,000Source | 1,796,000Source | 1,038,000Source | 1,195,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,545,000Source | 1,325,000Source | 1,115,000Source | 554,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,332,000Source | 10,138,000Source | 4,490,000Source | 2,352,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 596,000Source | -232,000Source | 770,000Source | -190,000Source |
| Increase (Decrease) in InventoriesUSD | 826,000Source | 464,000Source | 485,000Source | 478,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -35,103,000Source | -21,868,000Source | -16,376,000Source | -15,542,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -30,560,000Source | 12,641,000Source | -16,092,000Source | 8,441,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,662,000Source | 1,402,000Source | 381,000Source | 473,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 55,569,000Source | 18,452,000Source | 37,534,000Source | -140,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -9,977,000Source | 9,276,000Source | 5,008,000Source | -7,372,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,332,000Source | 10,138,000Source | 4,490,000Source | 2,352,000Source |
| DepreciationUSD | 476,000Source | 280,000Source | 232,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 14,000Source | — | 6,000Source | — |
| General and Administrative ExpenseUSD | 20,707,000Source | 15,306,000Source | 11,104,000Source | 8,356,000Source |
| Income Tax Expense (Benefit)USD | 63,000Source | 59,000Source | 65,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,786,000Source | -32,005,000Source | -19,916,000Source | -18,491,000Source |
| Nonoperating Income (Expense)USD | 891,000Source | 1,557,000Source | 1,292,000Source | 250,000Source |
| Operating ExpensesUSD | 52,263,000Source | 35,009,000Source | 22,950,000Source | 19,830,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | 19,000,000Source |
| Proceeds from Issuance of Common StockUSD | 1,000,000Source | 1,000,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 8,979,000Source | 7,009,000Source | 6,205,000Source | 5,171,000Source |
| Cost of RevenueUSD | 6,330,000Source | 5,503,000Source | 4,398,000Source | 4,054,000Source |
| Operating Income (Loss)USD | -49,614,000Source | -33,503,000Source | -21,143,000Source | -18,713,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -48,723,000Source | -31,946,000Source | -19,851,000Source | -18,463,000Source |
| Income Tax Expense (Benefit)USD | 63,000Source | 59,000Source | 65,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,786,000Source | -32,005,000Source | -19,916,000Source | -18,491,000Source |
| Earnings Per Share, BasicUSD per share | -0.76Source | -0.76Source | -0.82Source | -2.35Source |
| Earnings Per Share, DilutedUSD per share | -0.76Source | -0.76Source | -0.82Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 64,325,810Source | 41,928,360Source | 24,268,181Source | 7,871,814Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 64,325,810Source | 41,928,360Source | 24,268,181Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 476,000,000Source | 280,000,000Source | 232,000,000Source | 188,000Source |
| General and Administrative ExpenseUSD | 20,707,000Source | 15,306,000Source | 11,104,000Source | 8,356,000Source |
| Gross ProfitUSD | 2,649,000Source | 1,506,000Source | 1,807,000Source | 1,117,000Source |
| Nonoperating Income (Expense)USD | 891,000Source | 1,557,000Source | 1,292,000Source | 250,000Source |
| Operating ExpensesUSD | 52,263,000Source | 35,009,000Source | 22,950,000Source | 19,830,000Source |
| Other Cost of Operating RevenueUSD | 1,130,000Source | 805,000Source | — | — |
| Research and Development ExpenseUSD | 15,003,000Source | 13,634,000Source | 7,981,000Source | 7,810,000Source |
| Selling and Marketing ExpenseUSD | 16,553,000Source | 6,069,000Source | 3,865,000Source | 3,664,000Source |
Filing attachments
ex4-1.htm · 8-K · 2026-09-21
Exhibit 4.1 SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT INSPIREMD, INC. THIS SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT (this “ Amendment ”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “ Company ”), and the holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). WHEREAS, the Holder i…
Read attachment ↗ex4-2.htm · 8-K · 2026-09-21
Exhibit 4.2 Series K Common Stock Purchase Warrant AMENDMENT INSPIREMD, INC. THIS SERIES K COMMON STOCK PURCHASE WARRANT AMENDMENT (this “ Amendment ”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “ Company ”), and the holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). WHEREAS, the Holder i…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-21
Exhibit 99.1 InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised in full, together with existing cash balances, expected to provide additional resources to fund launch of CGuard Prime 80 cm following FDA approval - - No…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17th, at 8:30am EDT - Miami, FL - August 17, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated …
Read attachment ↗ex99-1.htm · 8-K · 2026-06-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures Miami, FL - June 11, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid …
Read attachment ↗ex99-1.htm · 8-K · 2026-05-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures - - FDA approval of the original CGuard delivery system anticipated in Q3 2026 - - On track for expected FDA approval of the CGuard Prime 80 cm for TCA…
Read attachment ↗